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[0001] The present invention relates to the use of polyamidoamines as antimalarial agents or carriers of antimalarial
drugs and to formulations thereof.
[0002] Malaria is one of the most serious and complex health problems affecting humanity, despite the work of the
research community towards its eradication. Malaria is an infectious disease caused by four species of the protozoan
parasite Plasmodium, P. falciparum being the most severe of the four. All attempts to develop completely protective
vaccines against P. falciparum have failed so far. Therefore, therapies and preventive measures against malaria are
based on drugs. Various classes of antimalarial drugs exist such as chloroquine sulphadoxine/pyrimethamine combi-
nation. These drugs have side effects and inconvenient dosing schedules which limit the compliance of patients. Moreover
resistance to many of the currently available antimalarial drugs is spreading rapidly, threatening people in areas where
malaria is endemic.
[0003] Nanovectors, such as liposomes, solid-lipid nanoparticles, nano and microemulsions have been receiving
attention to minimize the side effects of drug therapy. In vitro and in vivo tests on immunoliposomes generally indicate
that they selectively direct chloroquine towards Plasmodium-infected red blood cells (pRBCs) (M. Owais et al., Antimicrob
Agents Chemother., 39, 180-184, 1995). Liposomes can also prolong the duration of chloroquine exposure, acting as
a slow-release reservoir. However, little data are available on liposome-driven antimalarial drug targeting to human-
infecting parasites. Limited control over drug release, low encapsulation capacity, poor shelf stability, short in vivo
circulation times and difficult formulation for oral administration are some of the drawbacks of liposomes.
[0004] Biodegradable polymeric nanoparticles have shown a potential to increase the bioavailability of insoluble anti-
malarial drugs. Several polymeric nanocarriers have been proposed to deliver antimalarial drugs in vivo, including quinine,
halofantrine, curcumin, artemisinin derivatives, chloroquine, and primaquine. However, only few cases in the literature
describe in malaria-infected mice the efficacy of polymer-encapsulated drugs compared with the free compounds. Orally
administered lipid nanoemulsions of primaquine at a dose of 1.5 mg kg-1 day-1 improved the mean survival time of P.
berghei-infected mice from 13 to 39 days, and reduced parasitemia 4-fold relative to free drug (Singh, K.K. et al. Inter-
national Journal of Pharmaceutics 347, 136-143, 2008); oral delivery of curcumin bound to chitosan nanoparticles cured
all P. yoelii-infected mice when administered at 100 mg kg-1, whereas the same amount of the free drug cured only one
third of the animals (Akhtar, F. et al. Biotechnology Advances 30, 310-320, 2012); intravenous administration to P.
berghei-infected rats of several doses of 75 mg kg-1 day-1 quinine enclosed in nanocapsules prepared with poly(ε-capro-
lactone) and Polysorbate 80 improved by 30% the efficacy of free quinine (Haas, S.E. et al. International Journal of
Antimicrobial Agents 34[2], 156-161, 2009); finally, a single intravenous dose of 1 mg kg-1 halofantrine encapsulated in
poly(D,L-lactide)-based polymer cured 80% of P. berghei-infected mice, when the same dose of the free drug was unable
to arrest the infection or to prolong the survival of the animals (Mosqueira, V.C.F. et al. Antimicrobial Agents and Chem-
otherapy 48, 1222-1228, 2004).
[0005] Therefore the need remains of having anti-malarial drugs with increased activity, lower side effects and less
prone to induce Plasmodium resistance.
[0006] It has now unexpectedly been found that particular polyamidoamines (PAA) with amphoteric properties have
antimalarial activity per se. Furthermore it has been found that said PAA and their conjugates with proteins are able to
carry anti-malarial drugs into infected red blood cells. PAAs have been observed to increase the activity of the drugs.
[0007] Object of the present invention are amphoteric PAA having a MW of 10-100 kDa, for use in the treatment and/or
prevention of malaria.
[0008] Malaria may be caused by different species of Plasmodium, in particular Plasmodium falciparum, Plasmodium
vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi.
[0009] Preferred fractions are those having a MW of 10-30 kDa, 30-50 kDa, 50-100 kDa. Most preferred is the fraction
having a MW of 50-100 kDa.
[0010] The amphoteric PAA for the use of the present invention have the following formulae (I), (II) or (III):













wherein R1 and R3, which may be the same or different, are H or a group C1-6 alkyl, optionally substituted with a group
-COOH, -SO3H, -OPO3H, -OH, or -N(R7,R8) or -N(R7,R8, R9), in which anyone of R7, R8 and R9 independently is a
group C1-4 alkyl;
R4 and R6, which may be the same or different, are a group C1-6 alkyl, optionally substituted with a group -COOH,
-SO3H,-OPO3H, -OH, -N(R7,R8) or -N(R7,R8, R9)+, or -HN-C(NH2)=NH, in which R7, R8 and R9 are as above defined;
R2 and R5, which may be the same or different, are C1-C4 alkylene, optionally substituted with a group -(CH2)m-X,
wherein m is an integer between 0 and 6 and X is a group chosen among -COOH, -SO3H, -OPO3H, -OH, or -N(R7,R8)
or -N(R7,R8, R9)+ wherein R7,R8 and R9 are as above defined;
or the groups R1, R2 and R3, or the group R4, R5 and R6 together with the two adjacent nitrogen atoms form a saturated
heterocyclic group, optionally substituted with a C1-4 alkyl group.
n is an integer expressing the number of repeating units. The value of n is such as to give the reported molecular weight
of the polymer.
[0011] Preferably R1, R3, are H.
[0012] Preferably R2 is -CH2-, -CH(COOH)- or R1, R2 e R3, together with the two adjacent nitrogen atoms form a
saturated heterocyclic group:
[0013] The term amphoteric PAA means PAA containing both basic and acidic groups in their polymer backbone.
[0014] The amphoteric PAA of formula (I) or (II) and the methods for their preparation are disclosed in WO 2010/099962,
WO2011/145056 and in Ferruti P. et al., Biomacromolecules: 2007,8,1498-1504.
[0015] Amphoteric PAA of Formula (III) and methods for their preparation are disclosed in the Italian co-pending
application IT MI2012A000953 and in Ferruti et al. Journal of Polymer Chemistry: 2012, DOI: 10.1002/pola.26325.
[0016] The most preferred amphoteric PAA for the use of the present invention are:













[0017] The amphoteric PAA of the invention are able to target red blood cells infected by Plasmodium falciparum;
AGMA1, in addition, shows a significant antimalarial activity. Therefore the amphoteric PAA being biocompatible and
biodegradable polymers, are a new class of antimalarial agents with reduced side effects and might be less prone to
induce Plasmodium resistance than other targeting agents whose ligands are small antigenic regions.
[0018] The amphoteric polyamidoamine bearing guanidine residues in its main chain named AGMA1, reported above,
obtained by polyaddition of 2,2-bisacrylamiodacetic acid and 4-aminobutylguanidine, is a well-known bioactive and
biodegradable polymer, with an IC50>5 mg/ml and MTD>0.5 g/Kg in mice.
[0019] AGMA1 is known to play a role in the integrin-mediated adhesion to the extracellular matrix. In fact, it acts as
adhesion promoter of several primary cells, including neuronal cells (WO2010/099962). AGMA1 inhibits both HSV-1
and HSV-2 infection within the nanomolar range in vitro. It exerts its antiviral activity in vitro even when administered
before virus infection. It is resistant to acidic pH like that found in vagina and does not induce inflammatory response
and proves its antiviral activity in vivo.
[0020] It has now been found that AGMA1 has a significant antimalarial activity.
[0021] Another object of the present invention are the amphoteric PAA having a MW of 10-100 kDa, as defined above,
as carrier of antimalarial drugs and the compositions comprising the amphoteric PAA as defined above and antimalarial
drugs and their use in malaria treatment and/or prevention.
[0022] The anti malarial drugs can be selected from the group consisting of quinine and quinidine, atovaquone, chlo-
roquine and hydroxychloroquine, mefloquine, primaquine, artemisinin and their derivatives.
[0023] The compositions containing an amphoteric PAA and an antimalarial drug show a synergistic effect in compar-
ison to the sum of the effects of PAA and antimalarial drug alone.
[0024] A further object of the present invention are the conjugates of the amphoteric PAA of Formula (III) having a
MW of 10-100 kDa, preferably 50-100 kDa as defined above, with proteins for use as carrier of antimalarial drugs and
the compositions comprising conjugates of the amphoteric PAA of Formula (III) with protein as reported above and
antimalarial drugs and their use in the treatment and/or prevention of malaria. The protein is preferably an albumin or
acid alpha-1-glycoprotein.
[0025] The conjugates are obtained by reaction of the terminal acrylamide group of the PAA with SH or amine group
present in the protein. Preferred proteins are albumins and acid alphal-glycoprotein. The conjugates and their preparation
are disclosed in Ferruti et al. Journal of Polymer Science DOI: 10.1002/pola.26325 and in the co-pending application IT
MI2012A000953. Said conjugates have a high binding ability towards antimalarial drugs coupled with localization inside
red blood cells infected with Plasmodium. Particularly preferred are the conjugates of ISA23 with albumin obtained as
reported in the below Scheme 1.













[0026] The amphoteric PAA as described above, the compositions comprising the amphoteric PAA and an antimalarial
drug as described above and the composition comprising the conjugates of an amphoteric PAA with a protein and an
antimalarial drug as described above may be formulated with conventional carriers and excipients, which will be selected
in accord with ordinary practice.
[0027] Another object of the invention is a method for blocking transmission of malaria parasites comprising applying
an amphoteric polyamidoamine as defined above or a composition comprising an amphoteric PAA and an antimalarial
drug as defined above or a composition comprising a conjugates of an amphoteric PAA with a protein and an antimalarial
drug as described above to mosquitoes, in particular by feeding or spraying.
[0028] Excipients may include inter alia surfactants, preservatives, antioxidants, chelating agents, carbohydrates,
hydroxyalkylcellulose, hydroxyalkylmethyl-cellulose, poloxamer, polymeric stabilizing agents and the like. The pharma-
ceutical compositions include those suitable for different administration routes, such as for example oral, intravenous,
and parenteral. The pharmaceutical compositions may conveniently be presented in unit dosage form and may be
prepared by any of the methods well known in the art of pharmacy. When used for oral use for example, tablets, troches,
lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or
elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the
art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including
sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions or
suspensions containing the active ingredient(s).
[0029] The daily dosage of the polymer may vary from 100 to 1000 mg, preferably from 200 to 600 mg. The dosage
may be adjusted on the basis of efficacy, pharmaco-kinetic and toxicological studies. The dosage of anti-malarial drug
is that used for the drug alone or a lower dose.
Examples
Example 1: Synthesis of AGMA1
[0030] Linear AGMA1 was prepared by a procedure similar to that previously reported (Franchini et al., Biomacromol-
ecules, 2006, 7, 1215-1222). After that AGMA1 was ultrafiltered through membranes with nominal cut-off 100000, 50000,
30000, 10000, 5000, 1000, in order to obtain four AGMA1 with the following molecular weight range: 100000-50000,
30000-10000, 10000-5000, and 5000-1000.
Example 2: Synthesis of ISA23
[0031] Four linear ISA23 were synthesized as previously described (Richardson et al., J. Drug Targeting, 1999, 6 (6),
391-404). The crude reaction was ultrafiltered through membranes with nominal cut-off 100000, 30000, 10000, 3000,
1000, in order to obtain AGMA1 with the following molecular weight range: 100000-30000, 30000-10000, 10000-3000,
and 3000-1000.













Example 3: Preparation of the formulations ISA 23 - CHLOROQUINE/PRIMAQUINE SALTS
[0032] ISA23 was prepared as above reported (Mn=29800; PD=1.28). ISA23 (48% w/w aqueous solution, pH 10-11)
was brought to its isoelectric point (I.P.) (pH 5.2) by adding the exact amount of HCl(0.27 mL HClconc /g ISA23) necessary
to acidify the COO-Li+ equivalents borne in the repeating units of ISA23 as present in the polymerization mixture. The
crude polymerization mixture was then ultrafiltered through a membrane with molecular weight cut-off 5000. The final
product was retrieved by freeze-drying. It should be observed that ultrafiltration allows removing practically all LiCl
produced by acidification of ISA23, as ascertained by AgCl precipitation assay, which revealed the presence of only
traces of Cl-.
[0033] A 0.1 mg/mL methanol solution of PQ (or CQ) free base was added drop-wise to a 10 mg/mL ISA23 solution
at I.P. (pH 5.2) until pH 7-7.4 was obtained. The resultant clear solution was freeze-dried and the polymer salt retrieved
as a white powder.
Example 4: Preparation of the formulations AGMA 1- CHLOROQUINE/PRIMAQUINE SALTS
[0034] AGMA1 was prepared as above reported (Mn=20800; PD=1.38). A 10 mg/mL aqueous solution of AGMA1 pH
5.5 was first prepared. A 0.1 mg/mL methanol solution of PQ (or CQ) free base was added drop-wise to this solution
until pH 7-7.4 was reached. The resultant clear solution was freeze-dried and the product recovered as a white solid.
Example 5. Antimalarial activity of AGMA1 and ISA23
[0035] AGMA1 and ISA 23 samples (obtained as reported in examples 1 and 2) with different molecular weights were
tested as antimalarial agent in in vitro growth inhibition assays (GIAs). Parasitemia of P. falciparum 3D7 cultures was
adjusted to 1.5% with more than 90% of parasites at ring stage after sorbitol synchronization. 98 ml of this Plasmodium
culture was plated in 96-well plates and incubated in the presence of each polymer solution for 48 h at 37°C under a
gas mixture of 92% N2, 5% CO2, and 3% O2. Parasitemia was determined by microscopic counting of blood smears, or
by fluorescence-assisted cell sorting (FACS).
[0036] Results are reported in Table 1.
[0037] Inhibition of P. falciparum growth increased with polymer size, in good correlation with the increased binding
of higher molecular mass AGMA1 to pRBCs observed in FACS analysis. The highest antimalarial AGMA1 activity
corresponded to the 50-100-kDa fraction, which at a concentration of 1 mg/mL (10 mM for a 100-kDa polymer) reduced
parasitemia by 81.5%. AGMA1 IC50 in P. falciparum growth inhibition assays is around 0.25 mg/mL for the 50-100 kDa
fraction. The 30-100 kDa ISA23 fraction was observed to reduce parasitemia by 34.8% at 2 mg/mL.
Example 6. Specific targeting of ISA23 and AGMA 1 to infected RBCs
[0038] FITC-labelled AGMA1 (Mn=15500, PD=1.24) was prepared following the procedure previously described (Fer-
ruti, P. et al., Biomacromolecules 2007, 8 (5), 1498-1504). FITC-labelled ISA23 (Mn=12100, PD=1.56) was prepared
Table 1. Average and standard deviation of Plasmodium growth inhibition using different molecular weight fractions 
of AGMA1 and ISA 23 polymers. The values express percentage of reduction respective to the parasitemia of controls.




1 mg/mL 65.4 8.74 1 mg/mL 81.5 11.96
0.5 mg/mL 54.8 9.87 0.5 mg/mL 73.2 9.90
0.25 mg/mL 25.2 9.99 0.25 mg/mL 50.3 9.61
0.125 mg/mL 2.2 3.91 0.125 mg/mL 9.3 5.47




2 mg/mL 17.5 3.4 2 mg/mL 34.8 5.9
1 mg/mL 12.5 1.8 1 mg/mL 16.3 2.3
0.5 mg/mL 5.4 1.1 0.5 mg/mL 8.5 1.9
0.25 mg/mL 1.8 0.6 0.25 mg/mL 2.5 2.1













by treating with a FITC solution in methanol (0.2 mg/mL) a 10 mg/mL solution in buffer pH 7.4 of an ISA23 sample
(ISA23-NH2) carrying amine groups as side substituents. In turn, ISA23-NH2 was obtained by substituting 7% on a molar
basis of mono(tert-butoxycarbonyl)ethylenediamine for 2-methyl-piperazine. The mixture was stirred overnight at room
temperature and then centrifuged to eliminate insoluble impurities. The resultant clear solution was then dialyzed and
the fluorescein-labeled polymer isolated by freeze-drying the retained portion. The recovery was quantitative. The con-
jugation of ISA23-NH2 with FITC was confirmed by NMR and fluorescence microscopy and the efficiency of the labelling
procedure was determined by measuring the fluorescence intensity at λex=480 nm and λex=520 nm of a solution of
[0039] ISA23-FITC versus a standard FITC solution of known concentration.
[0040] Confocal fluorescence microscopy and flow cytometry were used to study the targeting of ISA23 or AGMA1 to
infected RBCs.
[0041] Fluorescein-labeled polymer at a concentration of 0.3 mg/mL was added to P.falciparum cultures of the 3D7
strain or to P.yoelii-infected mouse blood, and after 90 min of incubation polymer binding was detected by confocal
fluorescence and FACS.
[0042] Targeting analysis done by FACS indicated that FITC-labeled AGMA1 (Mn=15500) and ISA23 (Mn=12100)
polymers specifically target pRBCs. The specificity of targeting observed by FACS was also examined by confocal
fluorescence microscopy analysis of living pRBC cultures treated with FITC-labeled polymers. Both AGMA1 and ISA23
specifically target pRBCs infected by the P. falciparum late forms trophozoites and schizonts, but not ring-infected
pRBCs. After 90 min both polymers are detected inside target cells, in the close vicinity of DAPI-stained Plasmodium
DNA (this result has been confirmed by transmission electron microscopy). This targeting to pRBCs and to the parasite
itself can also be observed for the mouse malaria parasite P. yoelii, where the binding of ISA23 to merozoites (free
Plasmodium parasites) is particularly striking. This result offers interesting perspectives for PAAs as targeting elements
not only towards pRBCs but also towards free merozoites.
Example 7. In vitro antimalarial activity of compositions of PAA and chloroquine or primaquine.
[0043] Parasitemia of P. falciparum 3D7 cultures was adjusted to 1.5% with more than 90% of parasites at ring stage
after sorbitol synchronization. 98 mL of this Plasmodium culture was plated in 96-well plates and incubated in the presence
of phosphate-buffered saline (PBS) solutions of the free drugs or of polymer/drug conjugates (ISA 23-PQ obtained in
Example3; AGMA1-PQ obtained in Example 4,; ISA 23-CQ obtained in Example 3; AGMA1-CQ obtained in Example
4) for 48 h at 37°C under a gas mixture of 92% N2, 5% CO2, and 3% O2. Parasitemia was determined by microscopic
counting of blood smears, or by FACS.
Table 2. Effect of free primaquine, ISA23-PQ and AGMA1-PQ on the growth of P. falciparum. The polymers were 
















14.1 mg/mL 88.2 0.6 91.5 0.2 93.5 0.4
7.04 mg/mL 86.6 0.5 88.3 2.4 89.7 1.7
3.52 mg/mL 80.3 1.1 77.6 5.1 86.0 3.3
1.76 mg/mL 53.9 1.4 48.2 4.3 68.9 7.7
0.88 mg/mL 40.9 2.4 23.3 5.6 37.5 11.5
0.44 mg/mL 6.9 1.2 12.1 2.9 8.2 1.8
Table 3. Effect of free chloroquine, ISA23-CQ and AGMA1-CQ on the growth of P. falciparum. The polymers were 
















82.4 ng/mL 86.4 1.3 91.7 1.1 84.3 1.0
41.4 ng/mL 85.9 1.5 90.4 0.4 88.5 1.7













[0044] In standard GIAs, the non-covalent conjugation of AGMA1 and ISA23 with the antimalarial drugs primaquine
(AGMA1-PQ, ISA23-PQ) and chloroquine (AGMA1-CQ, ISA23-CQ) increased slightly the in vitro antimalarial activity of
the drugs. Covalent conjugation, on the other hand, significantly decreased drug efficacy (data not shown). Addition of
drugs and PAA-drug conjugates at trophozoite stage in a modified GIA or addition to either ring or trophozoite stage for
1 h before removing the drugs and incubating for a further 48 h before parasitemia determination improved the efficacy
of the encapsulated drugs relative to their free forms. These results suggest a potentiation of PAA-drug intake by pRBCs,
a result particularly remarkable for CQ, which has an endogenous carrier across human erythrocyte membranes that
accumulates the drug selectively in these cells.
Example 8. In vivo experiments with PAAs-chloroquine
[0045] The in vivo antimalarial activity of free chloroquine, ISA23-CQ and AGMA1-CQ (obtained as reported above)
was analyzed by using a 4-day-blood suppressive test as previously described (Fidock, D.A. et al. Nat. Rev. Drug Discov.
3, 509-520, 2004). Briefly, mice were inoculated 2 3 106 red blood cells from P. yoelii XL-infected mice by intraperitoneal
(ip) injection. The chemotherapy treatment started 2 hours later (day 0) with a single dose of 1 mg kg-1 day-1 chloroquine
(n=3) administered as free chloroquine, ISA23-CQ and AGMA1-CQ by an ip injection followed by identical dose admin-
istration for the following 3 days. Tested compounds were prepared at appropriate doses in PBS. The control groups
received PBS (n=3). The parasitemia was monitored daily by microscopic examination of Wright’s-stained thin-blood
smears. Activity was calculated by microscopic counting of blood smears from day 4.
[0046] In a 4-day suppressive test (Table 4), P. yoelii-infected mice were freed of parasites and cured after intraperi-
toneal administration of 4 3 1 mg kg-1 doses of CQ encapsulated in AGMA1 or ISA23, whereas the same or even a
larger amount of free CQ was unable to eliminate parasitemia or cure the animals.
[0047] The in vitro activity of encapsulated CQ was modest in comparison with its in vivo performance. This result
could be explained because the random encounters between pRBCs and polymers required for targeting specificity to
be manifested are favored by the turbulent mixing in the blood circulation. Alternatively, drug release could be facilitated
by some blood factor triggering polymer breakdown. In vitro, good PAA-mediated targeting might cancel out with slow
drug release from the polymers, resulting in no clear increase in encapsulated drug efficacy νs. its free form.
[0048] AGMA1 and ISA23 intrinsic pRBC targeting without the need for including bulky and often expensive ligands
will contribute to the design of smaller nanovectors, apt for oral formulation, and of lower cost, a desirable characteristic

















20.6 ng/mL 82.1 0.9 89.5 1.7 88.1 1.4
10.3 ng/mL 72.9 1.7 49.3 2.9 74.6 6.2
5.15 ng/mL 22.6 0.7 14.5 1.5 23.4 2.5
2.6 ng/mL 8.9 1.0 8.0 0.7 6.9 2.1
Table 4. Results of activity on day 4 in a 4-days suppressive test with malaria-infected mice of free chloroquine, and 
PAA-CQ formulations.
Sample % parasitemia Activity (% parasitemia reduction)
Control (PBS) 44.8
CQ 1 mg/kg 37.7 15.8 6 3.8
CQ 2.5 mg/kg 20.1 55.1 6 6.6
AGMA1-CQ 1 mg/kg 1.6 96.5 6 2.4
ISA23-CQ 1 mg/kg 7.4 83.5 6 7.8














1. An amphoteric polyamidoamine having a MW of 10-100 kDa for use in the treatment and/or prevention of malaria.
2. An amphoteric polyamidoamine having a MW of 30-50 kDa for use according to claim 1.
3. An amphoteric polyamidoamine having a MW of 50-100 kDa for the use according to claim 1.
4. The amphoteric polyamidoamine for the use according to each one of claims 1-3 which have the following formulae
(I), (II) or (III):
wherein R1 and R3, which may be the same or different, are H or a group C1-6 alkyl, optionally substituted with a
group -COOH, -SO3H, -OPO3H, -OH, or -N(R7,R8) or -N(R7,R8, R9), in which anyone of R7, R8 and R9 independently
is a group C1-4 alkyl;
R4 and R6, which may be the same or different, are a group C1-6 alkyl, optionally substituted with a group -COOH,
-SO3H,-OPO3H, -OH, -N(R7,R8) or -N(R7,R8, R9)+, or -HN-C(NH2)=NH, in which R7, R8 and R9 are as above defined;
R2 and R5, which may be the same or different, are C1-C4 alkylene, optionally substituted with a group -(CH2)m-X,
wherein m is an integer between 0 and 6 and X is a group chosen among -COOH, -SO3H, -OPO3H, -OH, or -N(R7,R8)
or -N(R7,R8,R9)+ wherein R7,R8 and R9 are as above defined;
or the groups R1, R2 e R3, or the group R4, R5 and R6 together with the two adjacent nitrogen atoms form a saturated
heterocyclic group, optionally substituted with a C1-4 alkyl group.
5. The amphoteric polyamidoamine for the use according to claim 4 wherein R1 and R3, are H, R2 is -CH2-, -CH(COOH)-
or R1, R2 and R3, together with the two adjacent nitrogen atoms form a saturated heterocyclic group of formula:













6. The amphoteric polyamidoamine for the use according to claim 1 having the formula:
7. The amphoteric polyamidoamine for the use according to claim 1 having the formula:
8. The amphoteric polyamidoamine for the use according to any one of claims 1-7 wherein malaria is caused by
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodiumknowlesi.
9. A pharmaceutical composition comprising an amphoteric polyamidoamine as defined in claims 1-7 and a pharma-
ceutically acceptable excipient and/or carrier.
10. An amphoteric polyamidoamine as defined in claims 1-7 for use as carrier of an antimalarial drug.
11. A composition comprising an amphoteric polyamidoamine as defined in claims 1-7 and an antimalarial drug.
12. The composition according to claim 11 wherein the antimalarial drug is selected from the group consisting of quinine
and quinidine, atovaquone, chloroquine and hydroxychloroquine, mefloquine, primaquine, artemisinin and their
derivatives.
13. The composition according to claim 11 or 12 for use in the treatment and/or prevention of malaria.
14. A conjugate of an amphoteric PAA of Formula (III) having a MW of 10-100 kDa as defined in claim 1 with a protein
for use as carrier of antimalarial drugs.
15. A composition comprising a conjugate of the amphoteric PAA of Formula (III) having a MW of 10-100 kDa as defined
in claim 1 with a protein and an antimalarial drug.
16. The composition according to claim 15 wherein the protein is an albumin or acid alpha-1-glycoprotein.
17. The composition of claim 15 or 16 for use in the treatment and/or prevention of malaria.
18. A method for blocking transmission of malaria parasites comprising applying a polyamidoamine as defined in claims
1-7 or a composition as defined in claim 11 or 12 or a composition as defined in claim 15 or 16 to mosquitoes.













19. The method according to claim 18 wherein a polyamidoamine as defined in claims 1-7 or a composition as defined
in claim 11 or 12 or a composition as defined in claim 15 or 16 is applied to mosquitoes by feeding or spraying.
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